How many insider trades does FilingIQ track for ENGN?

FilingIQ tracks 52 Form 4 insider transactions for ENGN (enGene Therapeutics Inc.), covering filings from Oct 31, 2023 onwards. 9 of those were filed in the last 90 days.

Are ENGN insiders net buyers or net sellers?

Across the full Form 4 history for ENGN, 15 transactions (29%) were open-market purchases and 3 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ENGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ENGN in?

enGene Therapeutics Inc. (ENGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $652.43M.

ENGN insider trading

Healthcare

enGene Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

29% / 6%

Market cap

$652.43M

About enGene Therapeutics Inc.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

Company website: www.engene.com

ENGN insider activity at a glance

FilingIQ has scored 52 insider transactions for ENGN since Oct 31, 2023. The most recent filing in our index is dated Jun 16, 2026.

Across the full history, 15 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ENGN insider trades is 50.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ENGN trades on FilingIQ Raw filings on SEC EDGAR

Latest ENGN Form 4 filings

Cooper Ronald Harold Wilfred Chief Executive Officer

P Sep 27, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,204

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 159

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

KALV 133

KalVista Pharmaceuticals, Inc.

Top insiders trading ENGN

HASTINGS PAUL J

4 trades · score 72.0

Frequently asked

How many insider trades does FilingIQ track for ENGN?: FilingIQ tracks 52 Form 4 insider transactions for ENGN (enGene Therapeutics Inc.), covering filings from Oct 31, 2023 onwards. 9 of those were filed in the last 90 days.
Are ENGN insiders net buyers or net sellers?: Across the full Form 4 history for ENGN, 15 transactions (29%) were open-market purchases and 3 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ENGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ENGN in?: enGene Therapeutics Inc. (ENGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $652.43M.

Methodology & sources

Every ENGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.